|drug1542||convalescent plasma Wiki||0.50|
|drug1280||Standard of Care Wiki||0.30|
|D018352||Coronavirus Infections NIH||0.05|
There is one clinical trial.
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care (SOC) can alleviate the immune-mediated cytokine release syndrome (CRS) and prevent progression to respiratory failure and/or death in high risk patients with COVID-19 pneumonia.
Description: Acute respiratory distress syndrome defined as new or worsening respiratory symptoms with PaO2/FiO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 315, chest imaging (radiograph, CT scan, or lung ultrasound) revealing bilateral opacities and pulmonary infiltrates not fully explained by fluid overload or cardiac failureMeasure: Incidence of acute respiratory distress syndrome (ARDS) Time: Up to 28 days
Description: Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0Measure: Percentage of Participants Experiencing Adverse Events Time: Up to 60 days
Description: Using the NCI CTCAE version 5.0Measure: Percentage of Participants Experiencing Serious Adverse Events Time: Up to 60 days